Therapeutic inhibition of CSF1R and MAPK signal transduction can effectively repolarize M2 macrophages into anti-tumor M1 phenotypes; A recent study suggests that the strategy of using supramolecular nanoparticles (DSN) loaded with dual kinase inhibitors aims to simultaneously inhibit both the CSF1R and MAPK signaling pathways, thereby reprogramming macrophages to enhance anti-tumor effects. This evidence concerns the gene CSF1R and neoplasm.